Acebrophylline 200mg SR + Fexofenadine10 mg + Monteleukast 10mg

Acebrophylline (Ambroxol + Theophylline-7-Acetate), another Xanthine derivative, is used as a bronchodilator for the treatment of bronchial asthma and COPD in adults. Acebrophylline modifies mucus secretion by lowering viscosity of ‘gel’ phase, increasing ‘sol’ phase and increases mucociliary clearance by augmenting ciliary motility. Acebrophylline inhibits intracellular phosphodiesterase and facilitates bronchial muscles relaxation by increasing cAMP levels. It selectively inhibits phosphatidyl choline and phospholipase A, TNF-alpha and leukotrienes. Inhibition of such pro-inflammatory mediators causes significant reduction of the airway inflammation and obstruction in chronic stages.

There are only few studies available on comparison between Acebrophylline and Sustained Release Theophylline in patients of COPD. The present study was designed to compare the efficacy of the two drugs in terms of lung function improvement and symptomatic benefit as well as tolerability/side-effects to help the patients to lead a socially and economically productive life.

Allergic Rhinitis (AR) is a global health problem. It is the cause of major illness and disability worldwide. Estimates indicate that 10-25% of population worldwide is affected by AR. The main symptoms of AR include nasal congestion, rhinorrhea, itching, sneezing and non-nasal symptoms like burning, itching and watery eyes or itching ears and palate. These symptoms can have a considerable toll on patient's quality of life by interfering with cognitive and emotional functioning. The estimated annual cost attributable to AR in United States ranges from $1.4 billion to nearly $ 6 billion in direct cost annually. Today's antiallergic therapy is based on avoidance of the causative allergen, symptomatic pharmacotherapy, specific immunotherapy and education. Oral/intranasal H1-antihistaminics, decongestants, leukotrienes receptor antagonists, intranasal corticosteroids are the pillars in the management of allergic rhinitis. Second generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to first generation counterparts.

Fexofenadine, is a selective, non sedating, second generation H1 receptor antagonist which have an additional impact on the inflammatory mediators.

Monteleukast is a highly selective type I receptor antagonist of leukotriene D4. The leukotrienes modifiers have both anti-inflammatory and bronchodilator properties